Dose-Finding, Safety, and Efficacy Study of XVR011 Added to Standard of Care in Patients Hospitalised for COVID-19

NCT04884295 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
27
Enrollment
INDUSTRY
Sponsor class

Stopped The sponsor does not intend to start Part 2 (Phase 2) due to change in company strategy for phase 2 design. This early end of trial is not due to reasons of safety or lack of efficacy. Part 1 (Phase 1) is completed as per protocol.

Conditions

Interventions

Sponsor

ExeVir Bio BV